Department of Psychiatry, University of Alberta Hospital, Edmonton, AB, Canada.
Acta Psychiatr Scand. 2010 Sep;122(3):192-210. doi: 10.1111/j.1600-0447.2009.01529.x. Epub 2010 Jan 25.
To review the literature on the involvement of glutamate (Glu), including its interactions with other neurochemical systems, in the pathophysiology of depression.
A MEDLINE search using the terms glutamate, depression and major depressive disorder, was performed.
Alterations in proteins involved in glutamatergic signalling are implicated in variations in behaviour in animal models of depression. Drugs acting at Glu receptors appear to have antidepressant-like effects in these models, and traditional antidepressant pharmacotherapies act on the glutamatergic system. Recent evidence from genetic studies and in vivo spectroscopy also correlate glutamatergic dysfunction with depression. Trials of N-methyl-d-aspartate receptor antagonists in humans have provided mixed results.
A growing body of evidence indicates that the glutamatergic system is involved in the pathophysiology of depression, and may represent a target for intervention.
综述谷氨酸（Glu）在抑郁症病理生理学中的作用，包括其与其他神经化学系统的相互作用。
使用术语谷氨酸、抑郁和重性抑郁障碍，在 MEDLINE 上进行了文献检索。
参与谷氨酸能信号转导的蛋白改变与抑郁症动物模型中的行为变化有关。在这些模型中，作用于 Glu 受体的药物似乎具有抗抑郁作用，传统的抗抑郁药物治疗作用于谷氨酸能系统。来自遗传研究和体内光谱学的最新证据也表明谷氨酸能功能障碍与抑郁症有关。在人类中进行的 N-甲基-D-天冬氨酸受体拮抗剂试验得出了混合结果。
越来越多的证据表明，谷氨酸能系统参与了抑郁症的病理生理学过程，可能成为干预的靶点。
